Reaction
Erosive Duodenitis reporting signals
As of the last recalculation, Erosive Duodenitis appears in 788 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is OLMESARTAN MEDOXOMIL (PRR 45.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Olmesartan Medoxomil | 57 | 45.1 | 45.1 |
| Basiliximab | 18 | 41.3 | 41.4 |
| Cefuroxime | 15 | 35.3 | 35.4 |
| Trimethoprim | 13 | 29.6 | 29.6 |
| Cholestyramine | 13 | 28.9 | 28.9 |
| Gemfibrozil | 16 | 28.4 | 28.4 |
| Tofacitinib Citrate | 12 | 24.5 | 24.6 |
| Ritonavir 100 Mg | 12 | 21.5 | 21.5 |
| Raltegravir | 13 | 21.1 | 21.1 |
| Doxazosin Mesylate | 26 | 19.6 | 19.6 |
| Doxazosin | 20 | 19.3 | 19.4 |
| Travoprost | 6 | 18.5 | 18.5 |
| Febuxostat Tablets 40 Mg | 7 | 18.3 | 18.3 |
| Febuxostat Tablets 80 Mg | 7 | 18.3 | 18.3 |
| Tiotropium Bromide Inhalation Spray | 7 | 16.6 | 16.6 |
| Lamivudine Oral | 15 | 15.9 | 16.0 |
| Gefitinib | 4 | 11.8 | 11.8 |
| Ipilimumab | 18 | 11.2 | 11.3 |